NNovadiol, Inc.: IP based drug with a short approval pathway, to address unmet needs of millions of patients worldwide - iCrowdNewswire

RSS Newsfeeds

See all RSS Newsfeeds

Apr 29, 2015 8:51 AM ET

NNovadiol, Inc.: IP based drug with a short approval pathway, to address unmet needs of millions of patients worldwide

iCrowdNewswire - Apr 29, 2015

Novadiol, Inc.

IP based drug with a short approval pathway, to address unmet needs of millions of patients worldwide.

Novadiol, Inc. is a C-Corporation that was incorporated in the State of Kansas on June 7, 2012. Its offices are located at 6425 Nieman Road, Shawnee Mission, KS 66203. Novadiol was formed to develop and globally market a vitamin D compound. G.P. Georges is the CEO and he has nearly 30 years of experience in the pharmaceutical industry. He is the owner of two successful companies: NephroTech Inc., a dialysis products firm, and NephroTech 1, LLC, a Calcium products firm.

The Problem We Solve

According to the National Kidney Foundation and the CDC, over 20 million US patients suffer from CKD just in the US. Over 4 MM of these patients have stage 3 or 4 CKD and suffer from SHPT. The incidence rates for SHPT in our other chosen markets are similar to those in the US. Hypovitaminosis D (Hypo-D), defined as 25OHD insufficiency/deficiency in the blood typically afflicts a third of the population in the US, EU, Australia and Japan. Thus just in Australia, the patient population is estimated at around 5.5 MM. Each of these markets represents significant opportunities even with low, conservative pricing. Currently patients take high daily doses of Vitamins D2 or D3 to treat Hypo-D, which show limited efficacy in raising 25OHD blood levels. Similarly in SHPT treatments, the current standard of care typically includes 1,25D analogues, which can cause imbalances in the calcium and phosphorus metabolism. Novadiol’s IP based product delivers a reliable, therapeutically effective increase in 25OHD without the side effects of the 1,25 analogues in SHPT or the variability of Vitamin D2 and D3 in Hypo D patients respectively. Cost effective, with a long duration of action, our therapy is a first-in-class for the SHPT/Hypo-D market aimed at delivering compliance and efficacy at a competitive, payer friendly price point, while generating significant profitability for our stakeholders.


Traction & Accomplishments

Novadiol is pursuing an IP based, 505(b)(2) NDA pathway in the USA. Our US NDA is expected to be filed in 2018-19 with approval and commercial launch in 2019-20. Because of the well researched, science based evidence of the clinical efficacy of our molecule Novadiol is in late stages in one of our other chosen markets. We are pursuing our CMC development with a leading CMO and we expect to file a NDA in this market in 2015. We expect to commercialize in this market in 2016 via partners. Our global development cost is expected to be $15 – $20 MM of which a substantial portion could be generated by out-licensing revenues from our late stage markets.


Clinical/Regulatory Details

Regulatory Status

We are currently preparing our IND package in the U.S, and our Dossier in foreign jurisdictions.



G.P. Georges (Founder)

• GP Georges is the Chief Executive Officer and has 32 years of experience in the pharmaceutical industry. For the past 20 years he has successfully marketed a number of dialysis products through his flagship company, Nephro-Tech Inc. In 2001 he took his second company, Nephro-Tech 1, LLC, through the patent acquisition and marketing processes for his calcium formate brand, Formical®. He has founded his third company, Novadiol, Inc., to develop and market a vitamin D compound used to treat vitamin D deficiency. Mr. Georges’ Nephro-Tech Inc.
Joseph Brickner (Founder)
Raj Riswadkar, MBA

Novadiol’s SVP of Business Development and Strategy. He has a wealth of experience in international business and corporate mergers. He has worked for Price Waterhouse, Accenture, KV Pharmaceutical Company and Express Scripts, in addition to working with numerous other companies as an independent international business consultant. He has an MBA from Cornell University and a Master’s degree in Engineering from the University of Toledo.
Joseph Brickner

Advisors/Board Members

Hector DeLuca, Ph.D. (Advisor)

President of Deltanoid Pharmaceuticals and former chair of the biochemistry department at the University of Wisconsin-Madison. Dr. DeLuca is considered one of the world’s foremost experts in the vitamin D field, and has over 300 patents to his name.
Contact Information:

G.P. Georges
Joseph Brickner
Raj Riswadkar
Joseph Brickner

Tags: , Crowdfunding
View Related News >